XML 82 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Capital Management (Tables)
 12 Months Ended
Dec. 31, 2023
Corporate information and statement of IFRS compliance [abstract]  
Schedule of total capital Our adjusted total capital base presented in the table below consists mainly of common shareholders’ equity, preferred shares and other equity instruments, equity in the participating account, non-controlling interests’ equity, CSM, and certain other capital securities that qualify as regulatory capital.
IFRS 17 and IFRS 9IFRS 4 and IAS 39
As atDecember 31, 2023January 1, 2023December 31, 2022
Subordinated debt$6,178 $6,676 $6,676 
Innovative capital instruments(1)
200 200 200 
Equity:
Preferred shares and other equity instruments2,239 2,239 2,239 
Common shareholders’ equity(2)
21,343 20,290 25,211 
Equity in the participating account457 268 1,837 
Non-controlling interests’ equity161 90 90 
Contractual Service Margin(3)
11,786 10,865 
Total capital(3)(4)
$42,364 $40,628 $36,253 

(1)    Innovative capital instruments are SLEECS issued by SLCT I (Note 12). SLCT I is not consolidated by us.
(2)    Common shareholders' equity is equal to Total shareholders' equity less Preferred shares and other equity instruments.
(3)    Effective January 1, 2023, the OSFI LICAT Guideline was updated to include CSM as part of Available Capital. Prior period restatements are not required.
(4)    For regulatory reporting purposes under the LICAT framework, there were further adjustments, including goodwill, non-life investments, and others as prescribed by OSFI, to the total capital figure presented in the table above.